This study aims to assess the feasibility of leveraging non-contrast CT and artificial intelligence to detect liver cancer in consecutive real-world patients. To this end, we deploy LEAF in a prospective real-world clinical setting for real-time monitoring, with a particular focus on flagging cases with liver cancer that may be missed by routine clinical workflow.
This prospective real-world trial will be conducted at FAHZU, a high-volume tertiary medical center in mainland China. LEAF will be deployed within the hospital information system through the DAMO Intelligent Medical Imaging interface, allowing it to flag potential liver lesions in real time. Approximately 2500 consecutive patients undergoing non-contrast CT examinations will be enrolled starting in July 2026. All incoming non-contrast chest and abdominal CT scans will be simultaneously reviewed by radiologists in routine clinical workflow and processed by LEAF in real-time. Daily logs of LEAF-positive alerts will be maintained by the research team. A prespecified clinical action committee composed of hepatobiliary surgeons and abdominal radiologists will review the case to assess whether the AI finding warrants communication to the treating physician of these patients. For patients with suspected malignant liver tumors, the committee's consensus on the presence of suspicious lesions will be communicated to their attending physicians, who will then decide whether additional diagnostic assessment is indicated according to standard clinical practice. The standard radiology workflow will not be altered by the study, and LEAF will be evaluated as a risk-stratification and case-flagging tool rather than a replacement for radiologist interpretation.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
2,500
The LEAF (Liver tumor dEtection And classiFication AI) model will assist in image interpretation. Patients with positive results for liver malignancy while not reported in standard-of-care CT report will be reviewed by a prespecified clinical action committee composed of hepatobiliary surgeons and abdominal radiologists will review the case and decide whether the AI finding warrants communication to the treating physician of these patients. For patients with suspected malignant liver tumors, the committee's consensus on the presence of suspicious lesions will be communicated to their attending physicians, who will then decide whether additional diagnostic assessment is indicated according to standard clinical practice, while remaining blinded to the LEAF results. The standard radiology workflow will not be altered by the study, and LEAF will be evaluated as a risk-stratification and case-flagging tool rather than a replacement for radiologist interpretation.
the First Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China
Detection accuracy in liver tumor assisted by LEAF (Liver tumor dEtection And classiFication AI)
Sensitivity, specificity of liver malignancy identification (defined as liver malignancy vs. liver benign tumor and non-tumor)
Time frame: Within 4 weeks after enrollment
AI diagnostic performance: patient-level Positive Predictive Value (PPV) and Negative Predictive Value (NPV) of liver malignancy identification
Time frame: Within 4 weeks after enrollment
Clinical utility: number of AI-detected and originally overlooked liver malignant lesions
recalled and pathologically confirmed
Time frame: Within 4 weeks after enrollment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.